169 related articles for article (PubMed ID: 38350880)
1. Tretinoin improves the anti-cancer response to cyclophosphamide, in a model-selective manner.
Tilsed CM; Morales MLO; Zemek RM; Gordon BA; Piggott MJ; Nowak AK; Fisher SA; Lake RA; Lesterhuis WJ
BMC Cancer; 2024 Feb; 24(1):203. PubMed ID: 38350880
[TBL] [Abstract][Full Text] [Related]
2. Retinoic Acid Induces an IFN-Driven Inflammatory Tumour Microenvironment, Sensitizing to Immune Checkpoint Therapy.
Tilsed CM; Casey TH; de Jong E; Bosco A; Zemek RM; Salmons J; Wan G; Millward MJ; Nowak AK; Lake RA; Lesterhuis WJ
Front Oncol; 2022; 12():849793. PubMed ID: 35402250
[TBL] [Abstract][Full Text] [Related]
3. Immunomodulatory properties of antineoplastic drugs administered in conjunction with GM-CSF-secreting cancer cell vaccines.
Nigam A; Yacavone RF; Zahurak ML; Johns CM; Pardoll DM; Piantadosi S; Levitsky HI; Nelson WG
Int J Oncol; 1998 Jan; 12(1):161-70. PubMed ID: 9454900
[TBL] [Abstract][Full Text] [Related]
4. Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth.
van der Most RG; Currie AJ; Cleaver AL; Salmons J; Nowak AK; Mahendran S; Larma I; Prosser A; Robinson BW; Smyth MJ; Scalzo AA; Degli-Esposti MA; Lake RA
PLoS One; 2009 Sep; 4(9):e6982. PubMed ID: 19746156
[TBL] [Abstract][Full Text] [Related]
5. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
Gold JE; Zachary DT; Osband ME
Int J Cancer; 1995 May; 61(4):580-6. PubMed ID: 7759164
[TBL] [Abstract][Full Text] [Related]
6. Cyclophosphamide enhances anti-tumor effects of a fibroblast activation protein α-based DNA vaccine in tumor-bearing mice with murine breast carcinoma.
Xia Q; Geng F; Zhang FF; Liu CL; Xu P; Lu ZZ; Xie Y; Sun B; Wu H; Yu B; Kong W; Yu XH; Zhang HH
Immunopharmacol Immunotoxicol; 2017 Feb; 39(1):37-44. PubMed ID: 28004985
[TBL] [Abstract][Full Text] [Related]
7. IMMUNEPOTENT CRP plus doxorubicin/cyclophosphamide chemotherapy remodel the tumor microenvironment in an air pouch triple-negative breast cancer murine model.
Santana-Krímskaya SE; Franco-Molina MA; Zárate-Triviño DG; Prado-García H; Zapata-Benavides P; Torres-Del-Muro F; Rodríguez-Padilla C
Biomed Pharmacother; 2020 Jun; 126():110062. PubMed ID: 32172064
[TBL] [Abstract][Full Text] [Related]
8. Tumor cell repopulation between cycles of chemotherapy is inhibited by regulatory T-cell depletion in a murine mesothelioma model.
Wu L; Yun Z; Tagawa T; Rey-McIntyre K; Anraku M; de Perrot M
J Thorac Oncol; 2011 Sep; 6(9):1578-86. PubMed ID: 21642867
[TBL] [Abstract][Full Text] [Related]
9. Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy.
Hanoteau A; Newton JM; Krupar R; Huang C; Liu HC; Gaspero A; Gartrell RD; Saenger YM; Hart TD; Santegoets SJ; Laoui D; Spanos C; Parikh F; Jayaraman P; Zhang B; Van der Burg SH; Van Ginderachter JA; Melief CJM; Sikora AG
J Immunother Cancer; 2019 Jan; 7(1):10. PubMed ID: 30646957
[TBL] [Abstract][Full Text] [Related]
10. Extended Tumor Control after Dendritic Cell Vaccination with Low-Dose Cyclophosphamide as Adjuvant Treatment in Patients with Malignant Pleural Mesothelioma.
Cornelissen R; Hegmans JP; Maat AP; Kaijen-Lambers ME; Bezemer K; Hendriks RW; Hoogsteden HC; Aerts JG
Am J Respir Crit Care Med; 2016 May; 193(9):1023-31. PubMed ID: 26652184
[TBL] [Abstract][Full Text] [Related]
11. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
12. Manipulating the Wnt/β-catenin signaling pathway to promote anti-tumor immune infiltration into the TME to sensitize ovarian cancer to ICB therapy.
Wall JA; Meza-Perez S; Scalise CB; Katre A; Londoño AI; Turbitt WJ; Randall T; Norian LA; Arend RC
Gynecol Oncol; 2021 Jan; 160(1):285-294. PubMed ID: 33168307
[TBL] [Abstract][Full Text] [Related]
13. Adoptive transfer of anti-CD3-activated CD4+ T cells plus cyclophosphamide and liposome-encapsulated interleukin-2 cure murine MC-38 and 3LL tumors and establish tumor-specific immunity.
Saxton ML; Longo DL; Wetzel HE; Tribble H; Alvord WG; Kwak LW; Leonard AS; Ullmann CD; Curti BD; Ochoa AC
Blood; 1997 Apr; 89(7):2529-36. PubMed ID: 9116299
[TBL] [Abstract][Full Text] [Related]
14. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
[TBL] [Abstract][Full Text] [Related]
15. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
[TBL] [Abstract][Full Text] [Related]
16. All-trans retinoic acid overcomes solid tumor radioresistance by inducing inflammatory macrophages.
Rao E; Hou Y; Huang X; Wang L; Wang J; Zheng W; Yang H; Yu X; Yang K; Bugno J; Ding X; Vokes E; Fu YX; Weichselbaum RR; Liang HL
Sci Immunol; 2021 Jun; 6(60):. PubMed ID: 34723044
[TBL] [Abstract][Full Text] [Related]
17. A novel retinoic acid receptor-γ agonist antagonizes immune checkpoint resistance in lung cancers by altering the tumor immune microenvironment.
Wei CH; Huang L; Kreh B; Liu X; Tyutyunyk-Massey L; Kawakami M; Chen Z; Shi M; Kozlov S; Chan KC; Andresson T; Carrington M; Vuligonda V; Sanders ME; Horowitz A; Hwu P; Peng W; Dmitrovsky E; Liu X
Sci Rep; 2023 Sep; 13(1):14907. PubMed ID: 37689790
[TBL] [Abstract][Full Text] [Related]
18. Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity.
Abe S; Nagata H; Crosby EJ; Inoue Y; Kaneko K; Liu CX; Yang X; Wang T; Acharya CR; Agarwal P; Snyder J; Gwin W; Morse MA; Zhong P; Lyerly HK; Osada T
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35039461
[TBL] [Abstract][Full Text] [Related]
19. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
20. CTLA-4 blockade expands infiltrating T cells and inhibits cancer cell repopulation during the intervals of chemotherapy in murine mesothelioma.
Wu L; Yun Z; Tagawa T; Rey-McIntyre K; de Perrot M
Mol Cancer Ther; 2012 Aug; 11(8):1809-19. PubMed ID: 22584123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
